US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities
Recommendation

Wednesday, 6 May 2026 9 .00 - 12.30 h
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
22.04.2026IPEC: Updated Qualification Guide
15.04.2026Ph. Eur.: Updated Guidelines for analytical Balances now available
08.04.2026EMA/CHMP: Updated Guideline on Active Substances published
01.04.2026CMDh/EMA: New Update to Appendix 1 on Nitrosamines
25.03.2026EDQM: How should the Specification of a Substance be Presented in a CEP Application?
25.02.2026EMA: Reflection Paper on Non-Mutagenic Impurities published


